Literature DB >> 15131084

Collaboration of Brca1 and Chk2 in tumorigenesis.

John Peter McPherson1, Bénédicte Lemmers, Atsushi Hirao, Anne Hakem, Jacinth Abraham, Eva Migon, Elzbieta Matysiak-Zablocki, Laura Tamblyn, Otto Sanchez-Sweatman, Rama Khokha, Jeremy Squire, M Prakash Hande, Tak W Mak, Razqallah Hakem.   

Abstract

Disruption of Brca1 results in cellular demise or tumorigenesis depending on cellular context. Inactivation of p53 contributes to Brca1-associated tumor susceptibility. However the activation of p53-dependent checkpoint/apoptotic signaling in the absence of Brca1 is poorly understood. Here, we show that Chk2 inactivation is partially equivalent to p53 inactivation, in that Chk2 deficiency facilitates the development, survival, and proliferation of Brca1-deficient T cells at the expense of genomic integrity. Brca1 deficiency was found to result in Chk2 phosphorylation and the Chk2-dependent accumulation and activation of p53. Furthermore, inactivation of Chk2 and Brca1 was cooperative in breast cancer. Our findings identify a critical role for Chk2 as a component of the DNA damage-signaling pathway activated in response to Brca1 deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131084      PMCID: PMC415639          DOI: 10.1101/gad.1192704

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  59 in total

1.  Tumorigenesis in mice carrying a truncating Brca1 mutation.

Authors:  T Ludwig; P Fisher; S Ganesan; A Efstratiadis
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

2.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

3.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

Authors:  X Xu; W Qiao; S P Linke; L Cao; W M Li; P A Furth; C C Harris; C X Deng
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

4.  A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells.

Authors:  J S Larson; J L Tonkinson; M T Lai
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

Review 5.  CHK2 kinase--a busy messenger.

Authors:  J Bartek; J Falck; J Lukas
Journal:  Nat Rev Mol Cell Biol       Date:  2001-12       Impact factor: 94.444

6.  The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.

Authors:  J Falck; N Mailand; R G Syljuåsen; J Bartek; J Lukas
Journal:  Nature       Date:  2001-04-12       Impact factor: 49.962

7.  Concomitant inactivation of p53 and Chk2 in breast cancer.

Authors:  Alexandra Sullivan; Martin Yuille; Claire Repellin; Archana Reddy; Olivier Reelfs; Alexandra Bell; Barbara Dunne; Barry A Gusterson; Peter Osin; Paul J Farrell; Isik Yulug; Abigail Evans; Tayfun Ozcelik; Milena Gasco; Tim Crook
Journal:  Oncogene       Date:  2002-02-21       Impact factor: 9.867

8.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

Review 9.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

Review 10.  Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor.

Authors:  Clare H McGowan
Journal:  Bioessays       Date:  2002-06       Impact factor: 4.345

View more
  31 in total

1.  Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.

Authors:  Prabodh K Kandala; Sanjay K Srivastava
Journal:  Mol Pharmacol       Date:  2010-05-05       Impact factor: 4.436

2.  Cross-talk between Chk1 and Chk2 in double-mutant thymocytes.

Authors:  Kathrin Zaugg; Yu-Wen Su; Patrick T Reilly; Yasmin Moolani; Carol C Cheung; Razquallah Hakem; Atsushi Hirao; Qinghua Liu; Stephen J Elledge; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

Review 3.  DNA-damage repair; the good, the bad, and the ugly.

Authors:  Razqallah Hakem
Journal:  EMBO J       Date:  2008-02-20       Impact factor: 11.598

4.  Loss of DNA polymerase zeta enhances spontaneous tumorigenesis.

Authors:  John P Wittschieben; Vaishali Patil; Veronika Glushets; Lisa J Robinson; Donna F Kusewitt; Richard D Wood
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

5.  RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.

Authors:  Parasvi S Patel; Karan Joshua Abraham; Kiran Kumar Naidu Guturi; Marie-Jo Halaby; Zahra Khan; Luis Palomero; Brandon Ho; Shili Duan; Jonathan St-Germain; Arash Algouneh; Francesca Mateo; Samah El Ghamrasni; Haithem Barbour; Daniel R Barnes; Jonathan Beesley; Otto Sanchez; Hal K Berman; Grant W Brown; El Bachir Affar; Georgia Chenevix-Trench; Antonis C Antoniou; Cheryl H Arrowsmith; Brian Raught; Miquel Angel Pujana; Karim Mekhail; Anne Hakem; Razqallah Hakem
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

6.  Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.

Authors:  Stéphanie Solier; Olivier Sordet; Kurt W Kohn; Yves Pommier
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

7.  Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer.

Authors:  Li Li; Marie-Jo Halaby; Anne Hakem; Renato Cardoso; Samah El Ghamrasni; Shane Harding; Norman Chan; Robert Bristow; Otto Sanchez; Daniel Durocher; Razqallah Hakem
Journal:  J Exp Med       Date:  2010-04-12       Impact factor: 14.307

8.  DNA double-strand break signaling and human disorders.

Authors:  Toshiyuki Bohgaki; Miyuki Bohgaki; Razqallah Hakem
Journal:  Genome Integr       Date:  2010-11-05

9.  Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

Authors:  Eunice L Kwak; Sang Kim; Jianmin Zhang; Robert D Cardiff; Emmett V Schmidt; Daniel A Haber
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Authors:  Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.